Literatur
-
1
Ryéden L, et al.
Tumor-specific expression of vascular endothelial growth factor receptor 2 is associated with impaired response to adjuvant tamoxifen in premenopausal breast cancer.
J Clin Oncol.
2005;
23 (21)
4695-704
-
2
Traina T A, Rugo H S, Caravelli J F, et al.
Feasibility trial of letrozole in combination with bevacizumab in patients with metastatic breast cancer.
J Clin Oncol.
2010;
28 (4)
628-33
-
3
Forero-Torres A, Saleh M N, Galleshaw J A, et al.
Pilot trial of preoperative (neoadjuvant) letrozole in combination with bevacizumab in postmenopausal women with newly diagnosed estrogen receptor- or progesterone receptor-positive breast cancer.
Clin Breast Cancer.
2010;
10 (4)
275-80
Korrespondierender Autor
Dr. Andrea Maisch
GBG Forschungs GmbH
Martin-Behaim-Straße 12
63563 Neu-Isenburg
Phone: + 49-6102-7480-327
Fax: +49-6102-7480-440
Email: Andrea.Maisch@germanbreastgroup.de
